Targets › KAT7
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.
Catalytic subunit of histone acetyltransferase HBO1 complexes, which specifically mediate acetylation of histone H3 at 'Lys-14' (H3K14ac), thereby regulating various processes, such as gene transcription, protein ubiquitination, immune regulation, stem cell pluripotent and self-renewal maintenance and embryonic development. Some complexes also catalyze acetylation of histone H4 at 'Lys-5', 'Lys-8' and 'Lys-12'…. (UniProt, O95251)
Open in Phaseline: the race on KAT7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| IDEAYA Biosciences | IDE574 KAT6/KAT7 co-inhibitor | KAT6, KAT7 | Phase 1 | Cancer | Dec 2029 |
Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.